(FDMT) 4D Molecular Therapeutics - Overview
Stock: Gene Therapy, Retinal Diseases, Cystic Fibrosis, Fabry Disease, Alpha-1
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 99.6% |
| Relative Tail Risk | -12.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 27.75 |
| Character TTM | |
|---|---|
| Beta | 1.262 |
| Beta Downside | 1.533 |
| Drawdowns 3y | |
|---|---|
| Max DD | 93.00% |
| CAGR/Max DD | -0.26 |
Description: FDMT 4D Molecular Therapeutics January 01, 2026
4D Molecular Therapeutics (NASDAQ: FDMT) is a late-stage biotech that leverages its proprietary Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors for ocular and systemic gene-therapy applications.
Its lead candidate, 4D-150, aims to treat retinal vascular diseases-including wet age-related macular degeneration (AMD) and diabetic macular edema-by delivering a single intravitreal injection that sustains anti-VEGF expression for multiple years, potentially displacing the current monthly anti-VEGF injection market, which is valued at > $8 billion globally.
Early-stage pipelines include 4D-710 for cystic fibrosis, 4D-175 for geographic atrophy, 4D-725 for α1-antitrypsin deficiency, and 4D-310 (Phase 1) for Fabry disease; the breadth of programs diversifies risk but also stretches cash resources.
Strategic collaborations with Astellas Gene Therapies, Arbor Biotechnologies, and uniQure provide both upfront licensing cash (≈ $30 M reported in 2024) and downstream development expertise, while the company’s cash runway of roughly 12 months (as of Q4 2025) underscores the importance of upcoming financing events.
Sector-wide, the AAV gene-therapy market is projected to grow at a CAGR of ~ 23 % through 2030, driven by regulatory incentives for rare-disease treatments and an aging population that expands the addressable pool for ocular indications.
For a deeper dive into FDMT’s valuation metrics and peer comparison, you might find the ValueRay platform useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -209.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -24.32 > 1.0 |
| NWC/Revenue: 229.4k% < 20% (prev 2.83m%; Δ -2.60m% < -1%) |
| CFO/TA -0.43 > 3% & CFO -183.5m > Net Income -209.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.1m) vs 12m ago 1.03% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.02% > 50% (prev 0.00%; Δ 0.02% > 0%) |
| Interest Coverage Ratio: -13.38 > 6 (EBITDA TTM -226.8m / Interest Expense TTM -16.9m) |
Altman Z'' -15.00
| A: 0.65 (Total Current Assets 312.4m - Total Current Liabilities 37.1m) / Total Assets 424.0m |
| B: -1.74 (Retained Earnings -735.7m / Total Assets 424.0m) |
| C: -0.44 (EBIT TTM -226.1m / Avg Total Assets 514.0m) |
| D: -13.36 (Book Value of Equity -735.0m / Total Liabilities 55.0m) |
| Altman-Z'' Score: -18.39 = D |
What is the price of FDMT shares?
Over the past week, the price has changed by +1.47%, over one month by +25.03%, over three months by -17.67% and over the past year by +37.88%.
Is FDMT a buy, sell or hold?
- StrongBuy: 5
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the FDMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.1 | 268.3% |
| Analysts Target Price | 33.1 | 268.3% |
| ValueRay Target Price | 8.5 | -5.8% |
FDMT Fundamental Data Overview February 03, 2026
P/B = 1.24
Revenue TTM = 120.0k USD
EBIT TTM = -226.1m USD
EBITDA TTM = -226.8m USD
Long Term Debt = 22.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.70m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.3m USD (from netDebt column, last quarter)
Enterprise Value = 223.4m USD (506.2m + Debt 22.3m - CCE 305.1m)
Interest Coverage Ratio = -13.38 (Ebit TTM -226.1m / Interest Expense TTM -16.9m)
EV/FCF = -1.21x (Enterprise Value 223.4m / FCF TTM -185.1m)
FCF Yield = -82.83% (FCF TTM -185.1m / Enterprise Value 223.4m)
FCF Margin = -154.2k% (FCF TTM -185.1m / Revenue TTM 120.0k)
Net Margin = -174.3k% (Net Income TTM -209.2m / Revenue TTM 120.0k)
Gross Margin = unknown ((Revenue TTM 120.0k - Cost of Revenue TTM 97.0m) / Revenue TTM)
Tobins Q-Ratio = 0.53 (Enterprise Value 223.4m / Total Assets 424.0m)
Interest Expense / Debt = 6.34% (Interest Expense 1.41m / Debt 22.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -178.6m (EBIT -226.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 312.4m / Total Current Liabilities 37.1m)
Debt / Equity = 0.06 (Debt 22.3m / totalStockholderEquity, last quarter 369.0m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -26.3m / EBITDA -226.8m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -26.3m / FCF TTM -185.1m)
Total Stockholder Equity = 442.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.70% (Net Income -209.2m / Total Assets 424.0m)
RoE = -47.27% (Net Income TTM -209.2m / Total Stockholder Equity 442.6m)
RoCE = -48.64% (EBIT -226.1m / Capital Employed (Equity 442.6m + L.T.Debt 22.3m))
RoIC = -40.36% (negative operating profit) (NOPAT -178.6m / Invested Capital 442.6m)
WACC = 10.34% (E(506.2m)/V(528.5m) * Re(10.57%) + D(22.3m)/V(528.5m) * Rd(6.34%) * (1-Tc(0.21)))
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.76%
Fair Price DCF = unknown (Cash Flow -185.1m)
EPS Correlation: 21.09 | EPS CAGR: 45.03% | SUE: 4.0 | # QB: 1
Revenue Correlation: -24.20 | Revenue CAGR: -0.58% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.93 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.48 | Chg30d=+0.000 | Revisions Net=+5 | Growth EPS=-6.8% | Growth Revenue=-40.2%